Six of 12 Relapsed or Refractory Indolent Lymphoma Patients Treated 10 Years Ago with 131I-Tositumomab Remain in Complete Remission-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Six of 12 Relapsed or Refractory Indolent Lymphoma Patients Treated 10 Years Ago with 131I-Tositumomab Remain in Complete Remission

Published:2011-05-13 Issue:6 Volume:52 Page:896-900
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Buchegger Franz,Antonescu Cristian,Helg Claudine,Kosinski Marek,Prior John O.,Delaloye Angelika Bischof,Press Oliver W.,Ketterer Nicolas

Publisher

Society of Nuclear Medicine

Subject

Radiology, Nuclear Medicine and imaging

Reference20 articles.

1. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University;Mac Manus;J Clin Oncol.,1996

2. Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience;Kaminski;Blood.,2000

3. Safety of Yttrium-90 Ibritumomab Tiuxetan Radioimmunotherapy for Relapsed Low-Grade, Follicular, or Transformed Non-Hodgkin’s Lymphoma

4. 131I-Tositumomab Therapy as Initial Treatment for Follicular Lymphoma

5. Tositumomab and Iodine I 131 Tositumomab for Recurrent Indolent and Transformed B-Cell Non-Hodgkin’s Lymphoma

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Response to ifosfamide, carboplatin, etoposide (ICE) vs. dexamethasone, cytarabine cisplatin (DHAP) as salvage chemotherapy in patients with relapsed/refractory lymphoma;Annals of Medicine & Surgery;2023-07-26

2. Monoclonal Antibody and Targeted Toxin Therapy;Holland‐Frei Cancer Medicine;2022-10-21

3. Radioimmunotherapy as the first line of treatment in non-Hodgkin lymphoma;Immunotherapy;2018-06

4. Monoclonal Serotherapy;Holland-Frei Cancer Medicine;2017-02-26

5. Radioimmunotherapy in non-Hodgkin lymphoma: Prediction and assessment of response;Critical Reviews in Oncology/Hematology;2016-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3